INT175482

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2003
Last Reported 2011
Negated 1
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 3.47
Pain Relevance 6.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
endothelial cells 2
CALM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
complementary and alternative medicine 580 100.00 Very High Very High Very High
Opioid 88 99.76 Very High Very High Very High
Inflammation 25 99.16 Very High Very High Very High
antagonist 22 99.12 Very High Very High Very High
agonist 96 98.82 Very High Very High Very High
cytokine 4 98.60 Very High Very High Very High
imagery 6 96.32 Very High Very High Very High
chronic pain syndrome 3 96.32 Very High Very High Very High
Lasting pain 79 93.68 High High
narcan 17 92.88 High High
Disease Link Frequency Relevance Heat
INFLAMMATION 28 99.16 Very High Very High Very High
Generalized Anxiety Disorder 2 97.86 Very High Very High Very High
Complex Regional Pain Syndromes 3 95.68 Very High Very High Very High
Pain 158 93.68 High High
Stress 11 91.20 High High
Low Back Pain 29 89.04 High High
Diabetes Mellitus 59 84.48 Quite High
Disease 50 83.96 Quite High
Juvenile Chronic Polyarthritis 37 77.12 Quite High
Bone Disease 13 75.84 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The third section of the survey, based on a review of Taiwanese and English language literature, focused on patterns of CAM use including: the reasons for CAM use, factors influencing the decision to use CAM, the administration of CAM with conventional treatments, the disclosure of CAM use to healthcare professionals, and the reasons for not using CAM or ceasing CAM.
Positive_regulation (using) of Neg (not) Gene_expression (ceasing) of CAM
1) Confidence 0.44 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952338 Disease Relevance 0.16 Pain Relevance 0
Respondents who indicated they had used any of the previously listed CAM therapies during the past 12 months were considered 'Recent' CAM users; respondents who indicated they have used one or more CAM therapies but not in the past 12 months were considered 'Past' CAM users; 'Never' CAM users included persons who indicated they have never used any CAM therapies.


Positive_regulation (used) of Gene_expression (therapies) of CAM associated with complementary and alternative medicine
2) Confidence 0.43 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2266896 Disease Relevance 0.24 Pain Relevance 0.54
Attitudes towards CAM
Positive_regulation (towards) of Gene_expression (Attitudes) of CAM associated with complementary and alternative medicine
3) Confidence 0.43 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2267156 Disease Relevance 0 Pain Relevance 0.23
The increase in CAM patronage and of constitutional claims to tax relief and reimbursement for CAM expenses has influenced debates about cost effectiveness, an index that has emerged as a crucial determinant of which CAM modality should obtain state funding.
Positive_regulation (increase) of Gene_expression (expenses) of CAM associated with complementary and alternative medicine
4) Confidence 0.43 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2952302 Disease Relevance 0.08 Pain Relevance 0.53
What type of CAM therapies should be utilized in patients using opioids?
Positive_regulation (utilized) of Gene_expression (therapies) of CAM associated with complementary and alternative medicine and opioid
5) Confidence 0.32 Published 2007 Journal BMC Complement Altern Med Section Body Doc Link PMC1885447 Disease Relevance 0.49 Pain Relevance 1.49
Kessler et al. [9] conducted a telephone survey of a stratified sample of 2055 adults and reported increasing demand for CAM therapies across all socioeconomic groups.
Positive_regulation (increasing) of Gene_expression (therapies) of CAM associated with complementary and alternative medicine
6) Confidence 0.32 Published 2007 Journal BMC Complement Altern Med Section Body Doc Link PMC1885447 Disease Relevance 0.54 Pain Relevance 0.93
Should patients be started on opioids before all appropriate CAM therapies have been exhausted?
Positive_regulation (appropriate) of Gene_expression (therapies) of CAM associated with complementary and alternative medicine and opioid
7) Confidence 0.32 Published 2007 Journal BMC Complement Altern Med Section Body Doc Link PMC1885447 Disease Relevance 0.57 Pain Relevance 1.56
Variations in CAM use
Positive_regulation (Variations) of Gene_expression (use) of CAM
8) Confidence 0.32 Published 2008 Journal BMC Complement Altern Med Section Body Doc Link PMC2424030 Disease Relevance 0.24 Pain Relevance 0.07
CAM surface expression by endothelial cells is regulated by cytokines and inflammatory activators.31 32 Previously, we have shown that the CAM expression in HIMECs was enhanced in response to dual inflammatory stimulation with TNF?
Positive_regulation (enhanced) of Gene_expression (expression) of CAM in endothelial cells associated with inflammation and cytokine
9) Confidence 0.16 Published 2008 Journal Gut Section Body Doc Link PMC2582343 Disease Relevance 0.37 Pain Relevance 0.15
Addition of inverse agonists or antagonists to the cell culture medium was reported to increase the level of expression of CAM GPCRs by stabilizing their conformation [19,20,27].
Positive_regulation (increase) of Gene_expression (expression) of CAM associated with antagonist and agonist
10) Confidence 0.12 Published 2003 Journal BMC Pharmacol Section Body Doc Link PMC317294 Disease Relevance 0.07 Pain Relevance 0.55
For example, mRNAs for glutamic acid decarboxylase (GAD) 1, microtubule-associated protein tau, serpin A, malate dehydrogenase, regulator of G-protein signaling, transferrin, s100 calcium binding protein, glutathione-S-transferase, calmodulin, ?
Positive_regulation (transferrin) of Gene_expression (transferrin) of calmodulin associated with generalized anxiety disorder
11) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2924890 Disease Relevance 0.57 Pain Relevance 0.36
, calcium-binding proteins such as calmodulin (presumably requiring pharmacological levels because of low affinity), calreticulin, nuclear calreticulin analogs, and two mitochondrial binding sites, one of which is located at the amphipathic ramp of complex 1 and displays high affinity to the indoleamine.19,21,43–45 The majority of synthetic agonists has not been tested for these binding sites, with the exception of ramelteon, which has a low affinity to quinone reductase 2,46 and does not seem to act via calmodulin.21
Positive_regulation (requiring) of Gene_expression (analogs) of calmodulin associated with agonist
12) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0.14 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox